Leerink Partnrs Issues Negative Estimate for Genfit Earnings

Genfit S.A. (NASDAQ:GNFT) – Research analysts at Leerink Partnrs reduced their FY2024 earnings estimates for Genfit in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn $0.60 per share for the year, down from their previous forecast of $0.61. The consensus estimate for Genfit’s current full-year earnings is $0.96 per share. Leerink Partnrs also issued estimates for Genfit’s FY2029 earnings at ($0.53) EPS.

Separately, HC Wainwright reissued a “buy” rating and issued a $13.00 price target on shares of Genfit in a research note on Friday, October 11th.

Genfit Price Performance

GNFT opened at $3.99 on Thursday. The company has a quick ratio of 3.74, a current ratio of 3.74 and a debt-to-equity ratio of 0.61. Genfit has a 12 month low of $3.35 and a 12 month high of $6.42. The firm’s fifty day simple moving average is $3.76 and its 200 day simple moving average is $4.43.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.